|Place of Origin:||China|
|Certification:||GMP, ISO 9001, USP|
|Model Number:||CAS 13647-35-3|
|Minimum Order Quantity:||Free samples Available|
|Packaging Details:||as your required|
|Delivery Time:||3-7 working days|
|Payment Terms:||Western Union, MoneyGram, T/T, Bitcoin|
|Supply Ability:||500-1000 kg / month|
|Appearance:||White Crystalline Powder||Biological Half-life:||8 Hours|
|Alias:||Vetoryl||Shipment::||FedEx, TNT, EMS, DHL.UPS,EUB|
raw hormone powders,
steroid powder source
Trilostane 99% Raw Powder Skin Disorder Alopecia for Dogs Cushing Disease
Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase which is used in the treatment of Cushing's syndrome.
It was withdrawn from human use in the United States market in April 1994.The drug was previously available in the United Kingdom for use in humans under the brand name Modrenal for the treatment of Cushing's disease and for breast cancer. It was approved in the United States in 2008 for the treatment of Cushing's disease (hyperadrenocorticism) in dogs under the brand name Vetoryl.
It was available by prescription in the UK under the Vetoryl brand name for some time before it was approved in the US. The drug is also used to treat the skin disorder Alopecia X in dogs.It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs. This prescription drug works by stopping the production of cortisol in the adrenal glands. In studies of the drug, the most common side effects were vomiting, lack of energy, diarrhea, and weight loss.
Trilostane should not be given to a dog that:
Veterinary Medicine — Dogs and Cushing’s Disease
Cushing’s disease is most common in smaller dogs. Signs of Cushing’s syndrome may include increased appetite, thirst and urination, hair loss, bald patches and an enlarged abdomen. Without treatment, dogs can develop weak and calcified skin patches, hepatopathy and frail abdominal muscles.
Canine Cushing’s disease is caused by excess secretion of the adrenocorticotropic hormone, which elevates cortisol levels. Most dogs that develop Cushing’s disease have pituitary dependant hyperadrenocorticism (PDH). Those who do not have Cushing’s because of PDH have an adrenocortical tumor, which may be benign or malignant. Whether the result of an adrenal or pituitary tumor, Cushing’s disease interferes with biological mechanisms that normally function to regulate cortisol blood levels.
As of 2008, Trilostane is an FDA approved treatment for dogs with Cushing’s disease. Administering Trilostane can inhibit with the production of cortisol in the adrenal glands, adjusting the adreno-cortico hormone levels and preventing disease symptoms.
Trilostane can be administered in once-daily doses, or in smaller, more frequent doses to reduce the occurrence of side effects. It may take approximately four weeks for the drug to take effect and to notice a reduction of symptoms.
Trilostane — Other Uses in Veterinary Medicine
In addition to treatment for pituitary dependant hyperadrenocorticism, adrenocortical tumors and Cushing’s disease, Trilostane may be used to treat dogs with Alopecia X. Advancements in veterinary medicine have also led to substantial groundwork in the use of trilostane for treating horses with Cushing’s.
Additionally, while PDH in felines is rare, trilostane may be a chosen form of therapy. However, trilostane has revealed to be a less successful form of treatment for cats.
|Related Categories||Androgen, Bioactive Small Molecule Alphabetical Index, Corticosteroid, Cytokines, Growth Factors and Hormones, Hormones,|
|color||white to tan|
|solubility||DMSO: ≥17 mg/mL|
Any needs, please contact me